BioCryst Pharmaceuticals
BCRX
238 hedge funds and large institutions have $915M invested in BioCryst Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 84 increasing their positions, 71 reducing their positions, and 27 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 71
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
1% more funds holding
Funds holding: 235 → 238 (+3)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.58% less ownership
Funds ownership: 87.89% → 87.32% (-0.58%)
15% less capital invested
Capital invested by funds: $1.08B → $915M (-$163M)
16% less call options, than puts
Call options by funds: $7.81M | Put options by funds: $9.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$26.4M |
| 2 |
Alkeon Capital Management
New York
|
+$13.7M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$10.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.09M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$6.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$24M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$13.2M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11.8M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$6.81M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.95M |
BCRX Hedge Fund Activity: Q1 2024 in Review
238 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2024, worth a combined $915M — down 15% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new BCRX positions and 27 closed out — a net gain of 4 holders — while 84 added to existing stakes and 71 trimmed.
The largest buyer was State Street, adding an estimated $26.4M. The largest seller was Morgan Stanley, cutting an estimated $24M.
- 238 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2024, up from 235 in Q4 2023.
- Funds reported $915M of BioCryst Pharmaceuticals stock for Q1 2024, down 15% quarter-over-quarter.
- 31 funds opened new BioCryst Pharmaceuticals positions in Q1 2024 and 27 closed out, a net change of +4 holders.
- The largest BioCryst Pharmaceuticals buyer in Q1 2024 was State Street, an estimated $26.4M added.
- The largest BioCryst Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $24M sold.
Based on aggregated 13F filings for Q1 2024.